This is an open-label, single arm, multi-center Phase II trial of entinostat given as a 5 mg
oral dose every week (days 1, 8, 15, and 22 of a 4-week cycle) in patients with relapsed or
refractory abdominal neuroendocrine (NE) tumors. Patients will continue on treatment until
disease progression or intolerable toxicity occurs.